Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

23.8%

5 terminated/withdrawn out of 21 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

38%

8 trials in Phase 3/4

Results Transparency

33%

5 of 15 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

9(42.9%)

Phase 3

7(33.3%)

Phase 1

4(19.0%)

Phase 4

1(4.8%)

21Total

Phase 2(9)

Phase 3(7)

Phase 1(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials

NCT07560150Phase 2Recruiting

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

Role: lead

NCT05539872Phase 2Completed

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Role: lead

NCT04207840Phase 4Completed

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

Role: lead

NCT01143051Phase 1Completed

Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers

Role: lead

NCT01460511Phase 3Completed

Evaluation of Efficacy and Safety of E004 in Children With Asthma

Role: lead

NCT01025648Phase 1Terminated

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.

Role: lead

NCT01188577Phase 1Completed

Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics

Role: lead

NCT01189396Phase 2Completed

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

Role: lead

NCT01581177Phase 2Completed

Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

Role: lead

NCT02271334Phase 2Completed

Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers

Role: lead

NCT02210806Phase 2Completed

Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation

Role: lead

NCT01174732Phase 2Completed

Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

Role: lead

NCT01476904Phase 3Completed

Safety Study in Adolescent and Adult Patients With Asthma

Role: lead

NCT01689363Phase 2Completed

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

Role: lead

NCT01255709Phase 2Completed

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

Role: lead

NCT01737892Phase 1Terminated

Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults

Role: lead

NCT01357642Phase 3Completed

Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients

Role: lead

NCT01737905Phase 3Completed

Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

Role: lead

NCT00634829Phase 3Terminated

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

Role: lead

NCT00635505Phase 3Terminated

Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients

Role: lead